Summary
Introduction
Javelin Pharmaceuticals is a late development stage specialty pharmaceutical company that discovers, develops and commercializes drugs and improved formulations of existing drugs that target pain management market.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Javelin Pharmaceuticals' product candidates include Dyloject, which is in Phase III development stage for the treatment of post-operative pain in the US. It's pipeline also include Rylomine, an intranasal formulation of morphine that is in Phase III for the treatment of acute moderate-to-severe pain and breakthrough pain in the US and Europe; Javelin Pharmaceuticals derives its entire revenues from grants received from the US Department of Defense (DOD) and the National Institutes of Health (NIH) for the development and clinical advancement of PMI-150. The company's total revenues increased at a CAGR of 31% during 2002-2006, from $0.3 million to $0.8 million. Javelin Pharmaceuticals is expected to witness an absolute growth of +$143 million with sales of $0.8 million in 2006 increasing to $143 million in 2010. The major contributor to this absolute growth is expected to be driven by the product launch of Dyloject in the year 2008 in most of the EU countries.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization .
|
